The size of the European Neurotherapeutics Market is projected to be rising at a prominent rate between 2021 to 2026.
Europe has the second-highest share in the market due to increasing awareness among people over various neurological conditions.
Neurological conditions result in damage to the brain, spinal nerves or column that is caused by injury or illness. The precise causes for many of the neurological conditions are not yet known. These disorders can affect men and women, young and old and people from all cultures. Some of these neurological conditions are life-long and people can experience them onset at any time in their lives. Some of these conditions like cerebral palsy, are present from birth, and Alzheimer’s disease, Parkinson’s disease affect mainly older people. These disorders involve progressive deterioration in mental and physical capabilities which disrupts the patient and patient’s family. So, Neurotherapeutics are used for the treatment of traumas causing diseases.
Europe Neurotherapeutics Market is mainly driven by increasing aging population, growing R&D expenditure, a better understanding of the nature of neurologic diseases. Aged population are more susceptible to brain disorders. Therefore, the rise in aging population and life expectancy of the people will increase the market. The restraints that will hamper the growth of the market are restrictions by regulatory bodies on various technologies and drugs.
Based on Treatment, the market is segmented into Neurologic drugs and Neurologic devices. Neurologic drugs are further classified into oral administration, injections and others. Whereas neurologic devices are further categorized into Electroconvulsive Therapy (ECT), Vagus Nerve Stimulation (VNS), transcranial magnetic stimulation, Deep Brain Stimulator, and others. Based on disorders, the market is segmented into Central Nervous system (CNS) disorders, Peripheral Nervous system (PNS) disorders, Autonomous Nervous system (ANS) disorders. Based on distribution channels the market is segmented into Hospitals, Neurotherapeutic center, Clinical research organizations, Clinics. Based on Geography, the Europe Neurotherapeutics market is analyzed under various regions namely U.K, Germany, France, Italy and Spain.
Some of the major players in Europe Neurotherapeutics Market are Abbott Laboratories, Inc., Becton, Novartis AG, Dickinson and Company, Pfizer, Inc., Johnson & Johnson, Biogen, Inc., GlaxoSmithKline, Inc., AstraZeneca plc, Sanofi-Aventis, Spiegelberg, stryker, Covidien, Medtronic, GE healthcare, and Merck & Co.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Neurologic Drugs
5.1.2.1 Oral Administration
5.1.2.2 Injections
5.1.2.3 Others
5.1.3 Neurologic Devices
5.1.3.1 Electroconvulsive Therapy (ECT)
5.1.3.2 Vagus Nerve Stimulation (VNS)
5.1.3.3 Transcranial magnetic stimulation
5.1.3.4 Deep Brain Stimulator
5.1.3.5 Others
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disorders
5.2.1 Introduction
5.2.2 Central Nervous system disorder
5.2.3 Peripheral Nervous system disorder
5.2.4 Autonomous Nervous system disorder
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Distribution Channels
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Neurotherapeutic center
5.3.4 Clinical Research organisations
5.3.5 Clinics
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By Disorders
6.1.3.4 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By Disorders
6.1.4.4 By Distributional Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By Disorders
6.1.5.4 By Distribution channels
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Becton
8.3 Novartis AG
8.4 Dickinson and Company
8.5 Pfizer
8.6 Johnson & Johnson
8.7 Biogen
8.8 Glaxosmithkline
8.9 AstraZeneca
8.10 Sanofi Aventis
8.11 Spiegelberg
8.12 Covidien
8.13 Medtronic
8.14 GE Health Care
8.15 Merck & Co
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
